Cinctive Capital Management LP
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 1787258
New York, NY
Position in REGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$7,168,553
+$2,272,582 QoQ
Shares Held
9,278
+46.3% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.49%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cinctive Capital Management LP holds $200,361,017 across 44 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
350,165 | $46,477,400 | |
| 2 | INSM |
INSMED Inc
|
161,996 | $17,272,013 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
26,712 | $13,268,651 | |
| 4 | CYTK |
Cytokinetics Inc
|
137,838 | $11,742,419 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
226,140 | $8,003,094 | |
| 6 | NTHI |
Neonc Technologies Holdings, Inc.
|
1,607,464 | $7,281,811 | |
| 7 | ERAS |
Erasca, Inc.
|
391,642 | $7,174,881 | |
| 8 | KRYS |
Krystal Biotech, Inc.
|
16,367 | $6,083,122 |
All Filings in REGN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7,168,553 | 9,278 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,895,971 | 6,343 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,089,116 | 1,937 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,632,225 | 3,109 | Shares | Sole | 2025-08-14 | |
| 2024-09-30 | $3,125,336 | 2,973 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $10,178,174 | 9,684 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $8,553,648 | 8,887 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $5,269,740 | 6,000 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||